HER2 MUTATION
Clinical trials for HER2 MUTATION explained in plain language.
Never miss a new study
Get alerted when new HER2 MUTATION trials appear
Sign up with your email to follow new studies for HER2 MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets tough lung cancers in first human trial
Disease control Recruiting nowThis study tests a new oral drug, BAY 2927088, for people with advanced non-small cell lung cancer that has specific EGFR or HER2 mutations. The trial has four parts to find the safest dose and see if the drug shrinks tumors. About 400 participants will take the drug daily until …
Matched conditions: HER2 MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill targets HER2 lung cancer in major trial
Disease control Recruiting nowThis Phase 3 trial is testing a new oral drug, sevabertinib, against standard intravenous chemotherapy for people with advanced non-small cell lung cancer that has specific HER2 mutations. About 444 participants will be randomly assigned to receive either sevabertinib twice daily…
Matched conditions: HER2 MUTATION
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill targets HER2 cancers in promising trial
Disease control Recruiting nowThis Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…
Matched conditions: HER2 MUTATION
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC